Meeting Coverage
Tumor Suppressor Genes Frequently Altered in Squamous Cell Carcinoma
Aug 17, 2022
Tumor suppressor genes, including TP53, TERT, KMT2D, NOTCH1, NOTCH2, and FAT1, were often altered...
Read MoreTreatment for Sézary Syndrome Increases
Aug 16, 2022
The use of systemic and skin-directed therapies increased among patients with Sézary syndrome...
Read MoreHigh Mortality Risk in Patients With Leukemia Hospitalized With CDI
Aug 16, 2022
Among patients with leukemia admitted to the hospital with Clostridioides difficile infection...
Read MoreVarious Racial Disparities in Patients With TP53m Acute Myeloid Leukemia
Aug 10, 2022
Black/Hispanic patients with TP53 mutation (m) acute myeloid leukemia (AML) had worse overall...
Read MoreVarious Racial Disparities in Patients With TP53m Acute Myeloid Leukemia
Aug 10, 2022
Black/Hispanic patients with TP53 mutation (m) acute myeloid leukemia (AML) had worse overall survival (OS) compared with White patients, according to study results presented by Talha Badar, MBBS, MD, at the 2022 American...
Read MoreOnce-Daily Radiotherapy Preferred by Patients With Limited Stage Small Cell Lung Cancer
Jul 14, 2022
High-dose, once-daily thoracic radiotherapy (TRT) and standard twice daily TRT were well tolerated...
Read MoreMost Patients With Multiple Sclerosis Experience Spasticity Daily
Jul 14, 2022
Most patients with MS experience spasticity daily, with varying degrees of severity and duration,...
Read MoreMultiple Sclerosis-Related Cognitive Impairment Perceptions Differ Between Patients & Physicians
Jul 14, 2022
Factors affecting self-reported cognitive impairment (CI) among patients with multiple sclerosis...
Read MoreQuadruple Therapy Phase II Data for EGFR-mutated NSCLC
Jul 11, 2022
Atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP) is a promising regimen for...
Read MoreDetermining Whether Adding RP1 to Cemiplimab Helps CSCC Patients
Jun 30, 2022
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read MoreAcalabrutinib Still Outperforming in R/R CLL: Three-years Follow-up of ASCEND
Jun 27, 2022
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read MoreOS benefit seen in 5-year data on ELEVATE-TN trial in CLL
Jun 21, 2022
A presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting, which was...
Read MoreAdd-on Tiragolumab Doesn’t Improve on Atezolizumab in Extensive Stage Small Cell Lung Cancer
Jun 17, 2022
A Late-breaking session at the American Society of Clinical Oncology (ASCO) 2022 Annual meeting,...
Read More